As mentioned above, patients with CH may have an enhanced response to T-cell-mediated therapies such as CAR-T cell therapy and bispecific T-cell engagers, particularly those with DNMT3A and TET2 loss-of-function variants, which tend to be proinflammatory and have been associated with greater antitumor activity and decreased T-cell exhaustion. Here, TET2 is linked to cyclic hematopoiesis.